Susan Abushakra

Alzheon, Inc. engages in the provision of medical development. It specializes in treatment for brain health, memory, and aging. It offers ALZ-801, an oral small molecule inhibitor of amyloid formation and neurotoxicity with potential to be a therapy for a genetically defined population of patients with or at high risk for Alzheimer's disease and other neurodegenerative disorders. The company was founded by Martin Tolar in June 2013 and is headquartered in Framingham, MA.

Bonti, Inc. develops novel treatments. It specializes in both aesthetic and therapeutic indications. The company was founded by Fauad Hasan, Mike Jarpe, Wajdie Ahmad, Jonathan Lim, David Ramsay and Susan Abushakra in 2015 and is headquartered in Newport Beach, CA.

Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada.

The Alzheimer's Association is based in Chicago, IL and has subsidiaries in the United States. The Alzheimer's Association provides information and resources for Alzheimer's and other dementias. Alzheimer’s Association was founded in 1980. Joanne Pike has been the CEO of the company since 2016.